Literature DB >> 21224465

Clinical referral patterns for carotid artery stenting versus carotid endarterectomy: results from the Carotid Artery Revascularization and Endarterectomy Registry.

Ryan B Longmore1, Robert W Yeh, Kevin F Kennedy, H Vernon Anderson, Christopher J White, Lance S Longmore, Kenneth Rosenfield, Kalon K L Ho, John A Spertus.   

Abstract

BACKGROUND: Carotid artery stenting (CAS) and carotid endarterectomy (CEA) are alternative strategies for stroke prevention in patients with atherosclerotic carotid disease. Although randomized clinical trials are the gold standard for assessing the relative benefits of different treatments, observational research is necessary for determining "real-world" effectiveness. Current recommendations limit the application of CAS to high-risk patients, undermining the ability to "balance" the characteristics of patients treated with either approach. We compared the clinical profiles of patients referred for CAS versus CEA in a large national database. METHODS AND
RESULTS: Clinical characteristics of 12 701 patients referred for CAS or CEA in the National Cardiovascular Data Registry-Carotid Artery Revascularization and Endarterectomy were compared for 44 clinical and demographic variables. To investigate the comparability of CAS and CEA patients, we stratified the cohort into quintiles of the propensity score for referral for CAS. Among 8069 patients referred for CAS and 4632 referred for CEA, the CAS patients had significantly more comorbidities. Whereas the propensity model balanced most covariates, the pooled standardized differences (≥10%) suggested persistent imbalance for ischemic heart disease, recent myocardial infarction, and restenosis of prior CAS/CEA, all of which were more common in the CAS group. After stratification of propensity scores by quintile, CEA patients comprised only 14% of the upper 2 quintiles.
CONCLUSIONS: Characteristics of patients referred for CAS differ markedly from those referred for CEA. Because of extreme clinical disparities between these patients, generalizable comparative effectiveness analyses of observational data will be difficult.

Entities:  

Mesh:

Year:  2011        PMID: 21224465     DOI: 10.1161/CIRCINTERVENTIONS.110.958843

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  6 in total

1.  Use of Propensity Scores To Design Observational Comparative Effectiveness Studies.

Authors:  Robert J Glynn
Journal:  J Natl Cancer Inst       Date:  2017-08-01       Impact factor: 13.506

2.  Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia.

Authors:  Gregory G Westin; Ehrin J Armstrong; Heejung Bang; Khung-Keong Yeo; David Anderson; David L Dawson; William C Pevec; Ezra A Amsterdam; John R Laird
Journal:  J Am Coll Cardiol       Date:  2013-12-04       Impact factor: 24.094

3.  Role of disease risk scores in comparative effectiveness research with emerging therapies.

Authors:  Robert J Glynn; Joshua J Gagne; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-05       Impact factor: 2.890

4.  Carotid artery stenting of a contralateral occlusion and in-hospital outcomes: results from the CARE (Carotid Artery Revascularization and Endarterectomy) registry.

Authors:  Nestor Mercado; David J Cohen; John A Spertus; Paul S Chan; John House; Kevin Kennedy; Ralph G Brindis; Christopher J White; Kenneth A Rosenfield; Steven P Marso
Journal:  JACC Cardiovasc Interv       Date:  2013-01       Impact factor: 11.195

5.  Risk prediction for adverse events after carotid artery stenting in higher surgical risk patients.

Authors:  Neil J Wimmer; Robert W Yeh; Donald E Cutlip; Laura Mauri
Journal:  Stroke       Date:  2012-11-05       Impact factor: 7.914

6.  Outcomes of carotid artery stenting at a high-volume Brazilian interventional neuroradiology center.

Authors:  Luis Henrique de Castro-Afonso; Guilherme Seizem Nakiri; Lucas Moretti Monsignore; Daniela dos Santos; Millene Rodrigues Camilo; Francisco Antunes Dias; Pedro Telles Cougo-Pinto; Clara Monteiro Antunes Barreira; Frederico Fernandes Alessio-Alves; Soraia Ramos Cabette Fábio; Octávio Marques Pontes-Neto; Daniel Giansante Abud
Journal:  Clinics (Sao Paulo)       Date:  2015-03-01       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.